Advertisement

International Journal of Colorectal Disease

, Volume 33, Issue 1, pp 71–78 | Cite as

Prognostic influence of hepatic margin after resection of colorectal liver metastasis: role of modern preoperative chemotherapy

  • Frank Makowiec
  • Peter Bronsert
  • Andrea Klock
  • Ulrich T. Hopt
  • Hannes P Neeff
Original Article

Abstract

Purpose

Modern chemotherapy (CTX) increases survival in stage IV colorectal cancer. In colorectal liver metastases (CLM), neoadjuvant (neo) CTX may increase resectability and improve survival. Due to widespread use of CTX in CLM, recent studies assessed the role of the hepatic margin after CTX, with conflicting results. We evaluated the outcome after resection of CLM in relation to CTX and hepatic resection status.

Methods

Since 2000, 334 patients with first hepatic resection for isolated CLM were analyzed. Thirty-two percent had neoadjuvant chemotherapy (targeted therapy in 42%). Sixty-eight percent never had CTX before hepatectomy or longer than 6 months before resection. The results were gained by analysis of our prospective database.

Results

Positive hepatic margins occurred in 8% (independent of neoCTx). Patients after neoCTX had higher numbers of CLM (p < 0.01) and a longer duration of surgery (p < 0.03). After hepatectomy, 5-year survival was 45% and correlated strongly with the margin status (47% in R-0 and 21% in R-1; p < 0.001). Survival also correlated with margin status in the subgroups with neoCTX (p < 0.01) or without neoCTx (p < 0.01). In multivariate analysis of the entire group, hepatic margin status (RR 3.2; p < 0.001) and age > 65 years (RR 1.6; p < 0.01) were associated with poorer survival. In the subgroup of patients after neoCTX (n = 106), only the resection margin was an independent predictor of survival (p < 0.001).

Conclusion

In patients with isolated colorectal liver metastases undergoing resection, the hepatic margin status was the strongest independent prognostic factor. This effect was also present after neoadjuvant chemotherapy for CLM.

Keywords

Colorectal liver metastasis Neoadjuvant chemotherapy Hepatic resection Resection margin Survival 

Notes

Acknowledgements

This manuscript is dedicated to Professor Ulrich T. Hopt, Head of the Department of Surgery of the University of Freiburg, who retired in 2016 after more than 40 years in Academic Surgery.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR, D'Angelica MI (2010) Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 210:744–752.  https://doi.org/10.1016/j.jamcollsurg.2009.12.040 CrossRefPubMedGoogle Scholar
  2. 2.
    Viganò L, Russolillo N, Ferrero A, Langella S, Sperti E, Capussotti L (2012) Evolution of long-term outcome of liver resection for colorectal metastases: analysis of actual 5-year survival rates over two decades. Ann Surg Oncol 19:2035–2044.  https://doi.org/10.1245/s10434-011-2186-1 CrossRefPubMedGoogle Scholar
  3. 3.
    Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T, Fédération Francophone de Cancérologie Digestive (FFCD) (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215.  https://doi.org/10.1016/S1470-2045(13)70447-9 CrossRefPubMedGoogle Scholar
  4. 4.
    Bonney GK, Coldham C, Adam R, Kaiser G, Barroso E, Capussotti L, Laurent C, Verhoef C, Nuzzo G, Elias D, Lapointe R, Hubert C, Lopez-Ben S, Krawczyk M, Mirza DF, LiverMetSurvey International Registry Working Group (2015) Role of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; an international multi-center data analysis using LiverMetSurvey. J Surg Oncol 111:716–724.  https://doi.org/10.1002/jso.23899 CrossRefPubMedGoogle Scholar
  5. 5.
    Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347–353CrossRefPubMedGoogle Scholar
  6. 6.
    Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH (2014) Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 25:1018–1025.  https://doi.org/10.1093/annonc/mdu088 CrossRefPubMedGoogle Scholar
  7. 7.
    Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715–722.  https://doi.org/10.1097/01.sla.0000160703.75808.7d CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bodingbauer M, Tamandl D, Schmid K, Plank C, Schima W, Gruenberger T (2007) Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg 94:1133–1138.  https://doi.org/10.1002/bjs.5762 CrossRefPubMedGoogle Scholar
  9. 9.
    Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Tabernero J, Teh C, Van Cutsem E, Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group (2012) The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17:1225–1239.  https://doi.org/10.1634/theoncologist.2012-0121 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Tanaka K, Nojiri K, Kumamoto T, Takeda K, Endo I (2011) R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy. Eur J Surg Oncol 37:336–343.  https://doi.org/10.1016/j.ejso.2011.01.007 CrossRefPubMedGoogle Scholar
  11. 11.
    Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, Kopetz S, Loyer EM, Curley SA, Abdalla EK, Vauthey JN (2013) Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 257:1079–1088.  https://doi.org/10.1097/SLA.0b013e318283a4d1 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sadot E, Groot Koerkamp B, Leal JN, Shia J, Gonen M, Allen PJ, DeMatteo RP, Kingham TP, Kemeny N, Blumgart LH, Jarnagin WR, DʼAngelica MI (2015) Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg 262:476–485.  https://doi.org/10.1097/SLA.0000000000001427 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R (2008) R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 248:626–637.  https://doi.org/10.1097/SLA.0b013e31818a07f1. PubMedGoogle Scholar
  14. 14.
    Ayez N, Lalmahomed ZS, Eggermont AM, Ijzermans JN, de Jonge J, van Montfort K, Verhoef C (2012) Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol 19:1618–1627.  https://doi.org/10.1245/s10434-011-2114-4 CrossRefPubMedGoogle Scholar
  15. 15.
    Laurent C, Adam JP, Denost Q, Smith D, Saric J, Chiche L (2016) Significance of R1 resection for advanced colorectal liver metastases in the era of modern effective chemotherapy. World J Surg 40:1191–1199.  https://doi.org/10.1007/s00268-016-3404-6 CrossRefPubMedGoogle Scholar
  16. 16.
    Hosokawa I, Allard MA, Gelli M, Ciacio O, Vibert E, Cherqui D, Sa Cunha A, Castaing D, Miyazaki M, Adam R (2016) Long-term survival benefit and potential for cure after R1 resection for colorectal liver metastases. Ann Surg Oncol 23:1897–1905.  https://doi.org/10.1245/s10434-015-5060-8 CrossRefPubMedGoogle Scholar
  17. 17.
    Neeff HP, Drognitz O, Klock A, Illerhaus G, Opitz OG, Hopt UT, Makowiec F (2012) Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. Int J Color Dis 27:635–645.  https://doi.org/10.1007/s00384-011-1360-z CrossRefGoogle Scholar
  18. 18.
    Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE, Soubrane O, Chaussade S, Mentha G, Terris B (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299–304.  https://doi.org/10.1093/annonc/mdl386 CrossRefPubMedGoogle Scholar
  19. 19.
    Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306–1315.  https://doi.org/10.1016/S1470-2045(15)00122-9 CrossRefPubMedGoogle Scholar
  20. 20.
    Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hägerstrand I, Ranstam J, Bengmark S (1986) Determinants of survival in liver resection for colorectal secondaries. Br J Surg 73:727–731.  https://doi.org/10.1002/bjs.1800730917 CrossRefPubMedGoogle Scholar
  21. 21.
    Cady B, Jenkins RL, Steele GD, Lewis WD, Stone MD, McDermott WV, Jessup JM, Bothe A, Lalor P, Lovett EJ, Lavin P, Linehan DC (1998) Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 227:566–571CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Shirabe K, Takenaka K, Gion T, Fujiwara Y, Shimada M, Yanaga K, Maeda T, Kajiyama K, Sugimachi K (1997) Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin. Br J Surg 84:1077–1080.  https://doi.org/10.1046/j.1365-2168.1997.02743.x CrossRefPubMedGoogle Scholar
  23. 23.
    Hamady ZZ, Lodge JP, Welsh FK, Toogood GJ, White A, John T, Rees M (2014) One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach. Ann Surg 259:543–548.  https://doi.org/10.1097/SLA.0b013e3182902b6e CrossRefPubMedGoogle Scholar
  24. 24.
    Margonis GA, Spolverato G, Kim Y, Ejaz A, Pawlik TM (2015) Intraoperative surgical margin re-resection for colorectal liver metastasis: is it worth the effort? J Gastrointest Surg 19:699–707.  https://doi.org/10.1007/s11605-014-2710-2 CrossRefPubMedGoogle Scholar
  25. 25.
    Viganò L, Procopio F, Cimino MM, Donadon M, Gatti A, Costa G, Del Fabbro D, Torzilli G (2016) Is tumor detachment from vascular structures equivalent to R0 resection in surgery for colorectal liver metastases? An observational cohort. Ann Surg Oncol 23:1352–1360.  https://doi.org/10.1245/s10434-015-5009-y CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of FreiburgFreiburgGermany
  2. 2.Comprehensive Cancer CenterUniversity of FreiburgFreiburgGermany
  3. 3.Institute of PathologyUniversity of FreiburgFreiburgGermany

Personalised recommendations